Medical startup Medii said on April 23 that it has built a physician collaboration system with the Japanese Society of Child Neurology to support the safe and appropriate use of Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene…
To read the full story
Related Article
- Elevidys Needs More Safety Data to Support Full Approval: Expert
June 18, 2026
- DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





